Wall Street Zen upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) from a strong sell rating to a sell rating in a report published on Saturday morning,Wall Street Zen reports.
ZNTL has been the topic of a number of other reports. Wedbush raised shares of Zentalis Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their target price for the company from $5.00 to $6.00 in a report on Tuesday, November 10th. Mizuho assumed coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They set an “outperform” rating and a $8.00 price target for the company. Leerink Partners initiated coverage on Zentalis Pharmaceuticals in a research report on Monday, October 5th. They set an “outperform” rating and a $8.00 price target on the stock. Jefferies Financial Group raised Zentalis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 14th. Finally, Rodman & Renshaw assumed coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.29.
View Our Latest Stock Analysis on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Trading Down 5.9%
NASDAQ:ZNTL opened at $1.60 on Friday. Zentalis Pharmaceuticals has a 1-year low of $1.28 and a 1-year high of $6.95. The firm has a fifty day simple moving average of $2.48 and a 200 day simple moving average of $3.38. The stock has a market capitalization of $114.67 million, a PE ratio of -0.83 and a beta of 1.91.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.20. On average, equities analysts predict that Zentalis Pharmaceuticals will post -1.80 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Zentalis Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of ZNTL. Toronto Dominion Bank lifted its stake in shares of Zentalis Pharmaceuticals by 278.1% during the 3rd quarter. Toronto Dominion Bank now owns 89,112 shares of the company’s stock worth $247,000 after buying an additional 65,546 shares during the last quarter. Empowered Funds LLC acquired a new position in Zentalis Pharmaceuticals in the 3rd quarter valued at about $211,000. 49 Wealth Management LLC acquired a new position in Zentalis Pharmaceuticals in the 3rd quarter valued at about $179,000. Russell Investments Group Ltd. raised its holdings in Zentalis Pharmaceuticals by 1,834.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 77,383 shares of the company’s stock valued at $214,000 after acquiring an additional 73,383 shares during the period. Finally, Jefferies Financial Group Inc. bought a new position in Zentalis Pharmaceuticals in the 3rd quarter valued at about $122,000.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer. Its research centers on therapies that target biological processes involved in tumor growth. The company’s lead drug candidate, azenosertib (formerly known as ZN-c3), is an investigational inhibitor of WEE1, a protein involved in cell-cycle regulation. It has been studied in clinical trials for ovarian cancer and other solid tumors. Zentalis has also advanced other oncology drug candidates, including compounds targeting cancer-related proteins.
See Also
- Five stocks we like better than Zentalis Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
